Sections
Title | Starting Page | Number of Pages |
---|
Table of Contents | 5 | 3 |
List of Tables | 6 | 1 |
List of Figures | 7 | 1 |
State of the Pharmaceutical Industry - Job Cuts and Site Closures | 8 | 17 |
Workforce Reduction | 8 | 2 |
Workforce Reduction by Job Type | 10 | 1 |
Site Closures | 11 | 3 |
Drivers for Workforce Reduction | 14 | 1 |
Mergers and Acquisitions | 14 | 1 |
Approval Rates and R&D Expenditure | 14 | 2 |
Investment in Innovative Science | 16 | 1 |
Late Stage Failures | 16 | 3 |
Complex Clinical Trials | 19 | 1 |
The Fourth Hurdle: Market Access Drug Pricing and Negotiation | 19 | 1 |
Growth of Generic Medicines | 20 | 3 |
Personalized Medicine and Diagnostics | 23 | 1 |
Future Outlook | 23 | 1 |
R&D Budgets | 23 | 2 |
Managing Staff During the Redundancy Process | 25 | 7 |
Managing the Transition | 25 | 1 |
Communicating with Employees Across the Organization | 25 | 1 |
Employee Consultations and Redundancy Conditions | 26 | 1 |
EU Countries | 26 | 2 |
US | 28 | 1 |
Supporting Employees during the Transition | 28 | 1 |
Networking | 28 | 1 |
Careers Fairs and Outplacement Services | 29 | 1 |
Productivity Following Restructuring | 29 | 1 |
Costs Associated with Restructuring Companies | 29 | 1 |
Morale | 30 | 1 |
Conclusions | 31 | 1 |
Managing Site Closures | 32 | 5 |
Site Redesign: Selling and Repurposing Sites | 34 | 1 |
Selling to CROs: GlaxoSmithKline s Zagreb and Verona Sites | 35 | 1 |
Case Study: Pfizer s Ann Arbor Site | 35 | 1 |
Case Study: AstraZeneca s Lund and Charnwood Sites | 35 | 1 |
Case Study: Pfizer s Sandwich Site | 36 | 1 |
Conclusion | 36 | 1 |
Planning for the Future | 37 | 14 |
Emerging Markets | 37 | 2 |
Outsourcing | 39 | 1 |
Outsourcing by Big Pharma | 39 | 1 |
Clinical Research | 39 | 1 |
Drug Discovery and Pre-clinical Research | 40 | 1 |
Small and Specialist CROs | 41 | 2 |
Spin-outs and Licensing | 43 | 2 |
Hubs, Clusters and Life Science Incubators | 45 | 1 |
Life Science Incubators | 45 | 2 |
Big Pharma Bioscience Incubators | 47 | 1 |
Pharma s Growth Close to Hubs and Clusters | 48 | 1 |
Working with Academia | 48 | 1 |
Employment Opportunities | 49 | 1 |
Conclusion | 49 | 2 |
Appendix | 51 | 4 |
Abbreviations | 51 | 1 |
References | 51 | 2 |
Methodology | 53 | 1 |
Primary Research | 53 | 1 |
Secondary Research | 53 | 1 |
Contacts Us | 53 | 1 |
Disclaimer | 54 | 1 |